T2 Biosystems Announces Issuer – GuruFocus.com

LEXINGTON, Mass., May 20, 2022 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (TTOO, Financial) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that the U.S. Patent and Trademark Office has issued patent number 11,326 213 (the ‘213 patent), “NMR Methods and Systems for the Rapid Detection of Tick-Transmitted Pathogens”. The ‘213 patent covers the T2Lyme™ panel, which identifies bacteria that cause Lyme disease directly from a patient’s blood in 3 to 5 hours. The T2Lyme panel runs on the T2Dx instrument®the same instrument currently used to perform the FDA-approved T2Bacteria® and T2 Candida® Panels.

Lyme disease is a debilitating disease caused by the bacteria Borrelia burgdorferi and is transmitted to humans through the bite of infected ticks. Typical symptoms include fever, headache, fatigue and skin rash called erythema migrans. If left untreated, the infection can spread to the joints, heart, and nervous system. Each year, approximately 30,000 cases of Lyme disease are reported to the Centers for Disease Control (“CDC”) by state health departments and the District of Columbia, however, recent estimates suggest that approximately 476,000 people are treated for Lyme disease each year in the United States.

Currently, there are no FDA-approved diagnostic tests for the sensitive detection of early Lyme disease. Laboratory diagnosis of Lyme disease has traditionally used a two-tiered process to detect the presence of antibodies against Borrelia burgdorferi in a patient’s blood. Antibodies are proteins found in the blood when the body reacts to a specific infection. In the case of Lyme disease, antibodies can take several weeks to develop, so patients may test negative using current FDA-approved diagnostics if a patient has recently been infected.

“The ‘213 patent, combined with our existing patent portfolio of 46 U.S. patents and 16 U.S. patent applications, as well as 73 international patents and patent applications, demonstrates the strength of our technology in identifying a range of pathogens directly from whole blood in 3-5 hours, allowing clinicians to ensure that patients receive the correct treatment faster and preventing the negative impact of a delay in receiving the correct treatment and overuse of antibiotics,” said John Sperzel, president and CEO of T2 Biosystems. “This US patent further demonstrates our commitment to advancing the development and commercialization of innovative diagnostic products for critical unmet healthcare needs.

About T2 Biosystems:

T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians efficiently treat patients faster than ever. T2 Biosystems products include T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel and the T2SARS-CoV-2™ Panel and are powered by proprietary T2 Magnetic Resonance (T2MR®) Technology. T2 Biosystems has an active pipeline of future products, including the T2Biothreat™ panel, T2Cauris™ panel and T2Lyme™ panel, as well as next-generation products for the detection of bacterial and fungal pathogens and antimicrobial resistance markers associates.

Investor contacts:
Philip Trip Taylor, Gilmartin Group
[email protected]